Cognosetta is a drug discovery company headquartered in Tampa, Florida. Founded in 2018, the company is focused on discovering therapeutic drugs for treating nervous system disorders.
At Cognosetta, we discover and develop ion channel and neuroreceptor modulators for therapeutic applications. Our mission is to advance innovative pharmacological solutions for tinnitus and other hearing disorders that currently lack FDA-approved medications. Cognosetta is founded on a combination of biological and clinical expertise, powerful small molecule and peptide ion channel modulators, proprietary preclinical methodology, and the determination to improve lives.
CogInc at Association for Research in Otolaryngology meeting
Cognosetta scientists present new findings that CS0023 modulates tinnitus-associated changes in neural activity and reduces signs of chronic tinnitus in a preclinical model.
February 21, 2021
CogInc Receives Bull Ring Accelerator Funding
The University of South Florida Foundation and USF Research Foundation have awarded Cognosetta the Bull Ring Accelerator Grant to support ongoing development of our Tinnitus treatment pipeline.
June 22, 2020
CogInc Awarded AOHL's Flexi Grant
Cognosetta, Inc. received the Flexi Grant Award from the Action on Hearing Loss Foundation to continue the development of our Tinnitus treatment pipeline. We are thankful to AOHL for their work supporting individuals with hearing loss and Tinnitus.
April 8, 2020
Partnership with IonCure
We are excited to announce our partnership with IonCure (http://ioncurerx.com/), an India-based start-up. Together we will utilize AI-based drug design to expand upon our safe, ion channel-targeted drug candidates. This partnership is funded in part by the Biotechnology Research Assistance Council (https://birac.nic.in/).
February 2, 2020
SBIR Grant Awarded
Cognosetta, Inc is excited to receive a SBIR Grant from the NIH to complete dosing and safety studies for Tinnitus pipeline candidates.
December 17, 2019
A patent for the small peptides discovered and developed by Cognosetta, Inc scientists has been fully granted.
February 1, 2019
Cognosetta, Inc. will continue to be head-quartered in Tampa, FL. An Austin, TX office has been added.
October 18, 2018
Stay tuned for new results!
A new study will soon be published at The Journal of Pharmacology and Experimental Therapeutics.
Cognosetta attends CeNeuro
CeNeuro 2018 Conference
June 25-28, 2018
Cognosetta forms as an LLC in Tampa, FL
June 18, 2018